SEC Form 10-Q filed by TNF Pharmaceuticals Inc.
$TNFA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
DEFR14A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)
10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)
PRER14A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)
SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)
Use of AI and machine learning accelerates identification of patient groups whose care can be improved First study examines pro-inflammatory TNF-α levels in patients receiving GLP-1 agonists including Wegovy® or Ozempic® Initial findings support opportunities to improve diagnosis and treatment and demonstrate isomyosamine's potential to impact quality of life in a general practice population TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need
Machine learning technology used to identify patients for studies of muscle mass preservation during GLP-1 treatment TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management. In keeping with FDA's recent draft Guidance on using Artificial Intelligence, the TNF-Renova partnership is ana
Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease biomarkers associated with TNF-alpha activation in elderly patients with sarcopenia TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that a platform presentation of an abstract titled "Isomyosamine for the Treatment of Sarcopenia in Older Adults" was delivered by Mitchell Glass, M.D., President and Chief Medical Officer of TNF, at the British Geriatrics Society (BGB) Spring Meeting 2025, hel
4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)
4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)
4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)
Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF